UAE Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

UAE Breast Cancer Therapeutics Market Analysis

$ 3999

The UAE breast cancer therapeutics market is expected to witness growth from $91 Mn in 2022 to $258 Mn in 2030 with a CAGR of 13.9% for the year 2022-2030. Market drivers for the UAE breast cancer therapeutics market are the rising prevalence of breast cancer and the development of new therapies for its treatment. The market is segmented by therapy, by cancer type, and by distribution channel. Gulf Pharmaceutical Industries JULPHAR, Pfizer, and Roche are some of the major companies in the market.

ID: IN10AEPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Parul Choudhary

Buy Now

UAE Breast Cancer Therapeutics Market Executive Analysis

The UAE breast cancer therapeutics market size is at around $91 Mn in 2022 and is projected to reach $258 Mn in 2030, exhibiting a CAGR of 13.9% during the forecast period. With total expenses of $17.17 Bn and total receipts of $17.32 bn, the UAE Federal Budget 2023 has been approved. The budget was divided among various federal expenses, government affairs, financial investments, social development, and social benefits. The healthcare and community protection budgets were each allocated $1.31 Bn, or 7.6% of the overall general budget. Social affairs received $0.95 Bn (5.6% of the overall general budget). The pensioners received $1.36 Bn, or 8% of the entire general budget. The UAE is a significant market for healthcare in the region. It spends over 3.5% of its gross domestic product on healthcare, with roughly 70% coming from state spending and barely 30% from the private sector. The UAE, one of the Middle East's most economically developed and diverse economies, has a solid healthcare system supported by advanced technologies.

According to the UAE-based study, women under the age of 40 had a substantially greater incidence of HER2-positive breast cancer than those in older age groups. Compared to western countries, the UAE has lower age-standardized rates for breast cancer incidence and mortality. This may be because the population is younger, is exposed to fewer risk factors, and has less screening frequency. Early onset, higher grade, a greater rate of HER2 amplification, and a lower rate of a luminal subtype are among the clinicopathologic and immune-histochemical characteristics of breast cancer in the UAE that differ from those in the Western population. Being the most prevalent cancer in the region, breast cancer has been a long-standing problem in the UAE. Due to a number of socioeconomic constraints, such as a lack of screening, the recent increase in breast cancer diagnoses has made the COVID-19 pandemic's already challenging healthcare system even worse.

uae breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The increasing prevalence of breast cancer in the UAE, the release of new oncology pharmaceuticals, and rising support for breast cancer research and development projects are some of the key market factors for breast cancer therapeutics in the UAE. Also improved insurance coverage policies for breast cancer contribute to the UAE breast cancer therapeutics market.

Market Restraints

The breast cancer therapies industry may suffer as a result of the UAE's already lower usage of screening diagnostics. Additionally, the associated increased costs of cancer medications and some targeted therapies, as well as side effects including neutropenia and radiation dermatitis, etc., seriously impede the market expansion in the UAE.

Competitive Landscape

Key Players

LIFEPharma (UAE)
Neopharma (UAE)
Gulf Pharmaceutical Industries JULPHAR (UAE)
Pfizer
Roche
Novartis
Bayer

Healthcare Policies and Regulatory Landscape.

Through various UAE health authorities, the UAE government has made a strong effort to promote early cancer identification. 2008 saw the start of screening programs for colorectal, breast, and cervical cancers at the Health Authority of Abu Dhabi. In 2014, the Dubai Health Authority began screening for colon, cervical, and breast cancer. The Ministry of Health officially launched a cancer screening campaign in September 2015 to increase awareness of cancer and the value of early diagnosis through routine physical examinations for colorectal, breast, and cervical cancers. The national health insurance program known as Thiqa in the UAE offers health insurance policies for breast cancer treatment. It includes a comprehensive range of breast cancer treatments, including screening and diagnostic investigations, surgeries, and rehabilitation therapies.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.